Tocilizumab for treating mevalonate kinase deficiency and TNF receptor-associated periodic syndrome: a case series and literature review
Abstract Background Mevalonate kinase deficiency (MKD) and TNF receptor-associated periodic syndrome (TRAPS) are categorized as systemic autoinflammatory diseases (SAIDs), which are rare diseases characterized by early onset, severe conditions, and challenging diagnosis and treatment. Although diffe...
Main Authors: | Yandie Li, Meiping Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-01-01
|
Series: | Pediatric Rheumatology Online Journal |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12969-023-00952-2 |
Similar Items
-
Compromised Protein Prenylation as Pathogenic Mechanism in Mevalonate Kinase Deficiency
by: Frouwkje A. Politiek, et al.
Published: (2021-09-01) -
Isolated neurological presentations of mevalonate kinase deficiency
by: Eva M. M. Hoytema van Konijnenburg, et al.
Published: (2023-01-01) -
Molecular mechanisms responsible for neuroinflammation and neurological impairments in mevalonate kinase deficiency
by: Maurizio Bifulco
Published: (2015-06-01) -
Mevalonate kinase deficiency syndrome: Single center experience
by: A. L. Kozlova, et al.
Published: (2021-07-01) -
A case of neonatal sweet syndrome associated with mevalonate kinase deficiency
by: Margaret Irwin, et al.
Published: (2023-09-01)